Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
For Immediate Release
Chicago, IL – November 27, 2024 – Today, Zacks Investment Ideas feature highlights InterDigital IDCC, Futu Holdings FUTU and Exelixis EXEL.
End of Year Rally: 3 Stocks to Watch
As the calendar year winds down, the stock market often heats up. The last five weeks of the year have historically shown a bullish seasonal pattern, fueled by holiday optimism, institutional portfolio adjustments, and a tendency for investors to position themselves for the upcoming year. This "Santa Claus rally" can provide lucrative opportunities for investors who know where to look.
Combining this favorable market seasonality with the Zacks Rank—a proven stock-picking strategy rooted in earnings estimate revisions—can further enhance your chances of uncovering big winners. By focusing on top-ranked stocks with fair valuations and strong growth you can align with this seasonal trend to maximize returns.
Today, we’ll highlight three such stocks—InterDigital, Futu Holdings and Exelixis, which all boast Top Zacks Ranks and discounted valuations based on growth forecasts.
InterDigital: Shares Rally on Huge Earnings Upgrades
InterDigital is a leader in mobile and video technology innovation, providing critical wireless and visual solutions to support global connectivity. The stock has soared over 80% year-to-date, showcasing strong investor interest and powerful momentum. Despite this impressive rally, IDCC remains attractively valued.
The company trades at a forward earnings multiple of just 12.7x, making it a bargain compared to its robust growth forecasts. Analysts project annualized EPS growth of 17.4% over the next three to five years, resulting in a PEG ratio of just 0.7—indicating significant value relative to its growth potential.
Adding to the bullish case, IDCC has experienced massive upward revisions in earnings estimates across all time frames. As shown in the table, consensus estimates for the current quarter have jumped by 262% in the past 60 days, while full-year forecasts are up over 46%. This level of earnings momentum gives InterDigital the coveted Zacks Rank #1 (Strong Buy) rating.
With strong fundamentals, bullish revisions, and a favorable valuation, InterDigital is a standout candidate in this year-end rally.
Exelixis: Strong Profit Growth Carries Stock Higher
Exelixis is a biotechnology company focused on developing and commercializing cancer therapies. Its flagship product, Cabometyx, has driven significant revenue growth, making Exelixis a standout in the biotech space. This growth, coupled with a robust pipeline of therapies in development, has drawn investor attention, pushing the stock up more than 50% year-to-date.
Despite its impressive performance, Exelixis remains attractively valued. The stock trades at a forward earnings multiple of just 18.8x, which is low for a biotech company with an annualized EPS growth forecast of 23.5% over the next three to five years. Its PEG ratio is 0.8, which is a discount based on the metric.
Analysts have been raising their earnings estimates for Exelixis significantly. Over the past 60 days, consensus estimates for the current quarter, next quarter, and full-year have all seen upward revisions. More specifically, full-year EPS estimates have increased by 5.5%, while next year's estimates are up 8.1%. These revisions higher give Exelixis a Zacks Rank #2 (Buy) rating, increasing the odds of a near-term rally.
Futu Holdings: Stock Boast Compelling Technical Setup
Futu Holdings is a leading digital brokerage platform serving clients in Hong Kong and mainland China. The company offers an array of financial services, including trading, wealth management, and market data, through its sleek, tech-driven app. Futu Holdings also enjoys a Zacks Rank #1 (Strong Buy) rating, reflecting upward trending earnings revisions.
Additionally, from a valuation perspective, Futu is highly attractive. The stock trades at a forward earnings multiple of just 17.5x, paired with robust EPS growth projections of 20.4% annually over the next three to five years. Its PEG ratio of 0.86 underscores its compelling value relative to its growth trajectory, signaling potential for significant upside.
Beyond fundamentals, Futu's technical chart presents an exciting setup. The stock is forming a descending wedge pattern—a bullish continuation signal—suggesting a breakout could be imminent. With Futu hovering near the wedge's apex, a breakout above resistance could attract momentum traders and drive the stock higher into the end of the year.
Should Investors Buy Shares in FUTU, EXEL and IDCC?
With the year-end rally potentially underway, stocks like Futu Holdings, Exelixis, and InterDigital present a compelling mix of strong growth, attractive valuations, and bullish setups. Each boasts upward-trending earnings revisions, solid fundamentals, and technical or momentum signals that align well with seasonal market trends.
While no investment is without risk, these stocks’ favorable growth profiles, combined with their Zacks Rank advantages, make them prime candidates to benefit from the “Santa Claus rally.” For investors looking to capitalize on this seasonal strength, FUTU, EXEL, and IDCC are worth considering.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research
By Kailyn Rhone
Oncology-focused biotech company Exelixis said the Food and Drug Administration will review its application to expand the use of its cancer drug, Cabozantinib.
The cancer drug is used to treat adults with advanced pancreatic and extra-pancreatic neuroendocrine tumors.
The FDA set a deadline of April 3 to decide whether to approve the expanded use of Cabozantinib, the company said Tuesday.
Exelixis plans to meet with the FDA's oncologic drugs advisory committee in March to discuss the drug's potential new uses. The meeting will review the safety and effectiveness of the cancer drug Cabozantinib for new uses, though it won't discuss the drug's current approved uses.
The committee will recommend to the commissioner of food and drugs whether the drug should be approved to treat additional cancer types.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.